Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
ABBISKO THERAPEUTICS上海和誉生物
{{company.company_channel.channel_name}}
Media Room
Latest
Photos
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting
2023-05-28 21:00
Abbisko presents the research results of 5 programs at the 2023 AACR Annual Meeting
2023-04-17 08:30
The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial
2023-03-16 10:00
Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib(ABSK021)
2023-01-30 11:00
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061
2022-07-04 13:34
1